Ser65
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser65  -  MAFA (human)

Site Information
PCSsVPSsPSFCAPS   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 5403102

In vivo Characterization
Methods used to characterize site in vivo:
mutation of modification site ( 1 , 2 , 3 ) , western blotting ( 1 , 3 )
Disease tissue studied:
pancreatic cancer ( 2 ) , pancreatic carcinoma ( 2 ) , diabetes mellitus ( 1 ) , insulinomatosis ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
ERK2 (human) ( 3 ) , MEKK1 (human) ( 3 )
Kinases, in vitro:
ERK2 (human) ( 3 )

Downstream Regulation
Effects of modification on MAFA:
activity, induced ( 3 )
Effects of modification on biological processes:
cell differentiation, altered ( 3 ) , transcription, induced ( 3 )

References 

1

Iacovazzo D, et al. (2018) missense mutation causes familial insulinomatosis and diabetes mellitus. Proc Natl Acad Sci U S A 115, 1027-1032
29339498   Curated Info

2

El Khattabi I, Sharma A (2013) Preventing p38 MAPK-Mediated MafA Degradation Ameliorates β-Cell Dysfunction under Oxidative Stress. Mol Endocrinol 27, 1078-90
23660596   Curated Info

3

Benkhelifa S, et al. (2001) Phosphorylation of MafA is essential for its transcriptional and biological properties. Mol Cell Biol 21, 4441-52
11416124   Curated Info